London, UK, 20 September 2023: PharmaVentures is pleased to announce it recently acted as exclusive M&A advisor on the sale of a European pharmaceutical services operation to a US corporation.
PharmaVentures led the complete sale process right through to closing. Both parties to the deal have chosen not to announce it publicly.
The sale is one of a number that PharmaVentures has completed in recent years and in a sector where it continues to excel including advising major pharmaceutical companies in the divestment of their manufacturing operations to key players in the pharmaceutical services sector.
The pharmaceutical services sector that includes CROs, CDMOs and other specialist consultancies has been undergoing significant change over recent years. Both new technological advances and the drive to reduce costs continue to provide an opportunity for both private equity and specialist companies to grow and diversify as the pharmaceutical industry evolves.
“This transaction highlights our track record in supporting the sale of specialist pharmaceutical services companies in the pharmaceutical industry,” said Dr Fintan Walton, CEO and Founder of PharmaVentures. “Our decades of experience in M&A, together with our detailed knowledge of the pharmaceutical services industry enabled us to deliver the optimal deal for our client.”
– Ends –
For further information, please contact:
Snr Marketing Manager
PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances.
For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies worldwide.
PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning.
PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
PharmaVentures’ services include:
- M&A (divestments, mergers, acquisitions, and strategic transactions)
- Licensing (in and out licensing)
- Fundraising Support
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuations (licensing, M&A, and fundraising)
- Pricing and Market Access
PharmaVentures is based in London, UK, and employs over 30 professionals and has associates in Europe and Asia-Pacific.
NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.
For more details, visit https://www.pharmaventures.com
Follow us on LinkedIn: https://www.linkedin.com/company/pharmaventures/